Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients

Plain-language summary

This observational study evaluates the real-world costs and outcomes of Panitumumab treatment in patients with metastatic colorectal cancer. Adults aged 18 and older with EGFR expression who were scheduled for third-line panitumumab with wild-type KRAS, or standard care with mutant KRAS, were able to take part. It was conducted as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

PeriPharm

Start date

4/1/2014

Estimated completion

3/1/2018

Countries

Canada

Related genes

Locations

• Lévis, Canada
• Montreal, Canada
• Montreal, Canada
• Sherbrooke, Canada
• Québec, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with a histologically confirmed diagnosis of mCRC.
* Immunohistochemical evidence of EGFR expression.
* ECOG performance status of 0, 1 or 2.
* Patients refractory to fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens
* Patients with a wt KRAS scheduled to receive panitumumab as a single agent for the third-line treatment of mCRC or patients with a mt KRAS scheduled to receive SOC for third-line treatment of mCRC.
* Signed and dated IRB-approved informed consent document.
* Ability to read and understand English or French.
* 18 years of age or older.